| 000 | 01755 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517161523.0 | ||
| 264 | 0 | _c20170717 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1536-5964 | ||
| 024 | 7 |
_a10.1097/MD.0000000000007268 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKwak, Yoo-Kang | |
| 245 | 0 | 0 |
_aTreatment outcome of diffuse large B-cell lymphoma involving the head and neck: Two-institutional study for the significance of radiotherapy after R-CHOP chemotherapy. _h[electronic resource] |
| 260 |
_bMedicine _cJun 2017 |
||
| 300 |
_ae7268 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Observational Study | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 | _aAntineoplastic Combined Chemotherapy Protocols |
| 650 | 0 | 4 |
_aChemoradiotherapy _xadverse effects |
| 650 | 0 | 4 | _aCyclophosphamide |
| 650 | 0 | 4 | _aDoxorubicin |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aHead and Neck Neoplasms _xdiagnosis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 | _aPrednisone |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aRadiotherapy, Intensity-Modulated _xadverse effects |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVincristine |
| 700 | 1 | _aChoi, Byung-Ock | |
| 700 | 1 | _aKim, Sung Hwan | |
| 700 | 1 | _aLee, Joo Hwan | |
| 700 | 1 | _aKang, Dae Gyu | |
| 700 | 1 | _aLee, Jong Hoon | |
| 773 | 0 |
_tMedicine _gvol. 96 _gno. 25 _gp. e7268 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MD.0000000000007268 _zAvailable from publisher's website |
| 999 |
_c27302318 _d27302318 |
||